<s id="wsj_0318.1"> 47
1 	 0 	 N/N 	 1 	 Inc. Lyphomed
1 	 15 	 (S[dcl]\NP)/S[dcl] 	 1 	 Inc. said
3 	 15 	 (S[dcl]\NP)/S[dcl] 	 1 	 Rosemont said
5 	 15 	 (S[dcl]\NP)/S[dcl] 	 1 	 Ill. said
10 	 8 	 N/N 	 1 	 Inc. Medco
10 	 9 	 N/N 	 1 	 Inc. Research
10 	 15 	 (S[dcl]\NP)/S[dcl] 	 1 	 Inc. said
13 	 12 	 N/N 	 1 	 Angeles Los
13 	 15 	 (S[dcl]\NP)/S[dcl] 	 1 	 Angeles said
17 	 16 	 NP[nb]/N 	 1 	 Food the
17 	 21 	 (S[dcl]\NP)/NP 	 1 	 Food granted
20 	 16 	 NP[nb]/N 	 1 	 Administration the
20 	 19 	 N/N 	 1 	 Administration Drug
20 	 21 	 (S[dcl]\NP)/NP 	 1 	 Administration granted
21 	 15 	 (S[dcl]\NP)/S[dcl] 	 2 	 granted said
24 	 21 	 (S[dcl]\NP)/NP 	 2 	 approval granted
24 	 22 	 N/N 	 1 	 approval full
24 	 23 	 N/N 	 1 	 approval marketing
24 	 25 	 (NP\NP)/NP 	 1 	 approval for
28 	 25 	 (NP\NP)/NP 	 2 	 drug for
28 	 26 	 NP[nb]/N 	 1 	 drug a
28 	 27 	 N/N 	 1 	 drug new
28 	 29 	 (NP\NP)/NP 	 1 	 drug for
31 	 29 	 (NP\NP)/NP 	 2 	 treatment for
31 	 30 	 NP[nb]/N 	 1 	 treatment the
31 	 32 	 (NP\NP)/NP 	 1 	 treatment of
34 	 32 	 (NP\NP)/NP 	 2 	 condition of
34 	 33 	 NP[nb]/N 	 1 	 condition a
34 	 36 	 ((NP\NP)/S[dcl])\((NP\NP)/NP) 	 1 	 condition which
35 	 36 	 ((NP\NP)/S[dcl])\((NP\NP)/NP) 	 3 	 in which
38 	 37 	 NP[nb]/N 	 1 	 heart the
38 	 39 	 (S[dcl]\NP)/NP 	 1 	 heart beats
39 	 36 	 ((NP\NP)/S[dcl])\((NP\NP)/NP) 	 2 	 beats which
41 	 40 	 (N/N)/(N/N) 	 2 	 150 between
43 	 40 	 (N/N)/(N/N) 	 2 	 200 between
44 	 39 	 (S[dcl]\NP)/NP 	 2 	 beats beats
44 	 41 	 N/N 	 1 	 beats 150 <XU>
44 	 43 	 N/N 	 1 	 beats 200
44 	 45 	 (NP\NP)/N 	 1 	 beats a
46 	 45 	 (NP\NP)/N 	 2 	 minute a
<\s>
<s id="wsj_0318.2"> 14
1 	 0 	 NP[nb]/N 	 1 	 condition The
1 	 3 	 (S[pss]\NP)/PP 	 1 	 condition known <XB>
1 	 9 	 (S[dcl]\NP)/PP 	 1 	 condition leads
4 	 3 	 (S[pss]\NP)/PP 	 2 	 as known
7 	 4 	 PP/NP 	 1 	 tachycardia as
7 	 5 	 N/N 	 1 	 tachycardia paroxysmal
7 	 6 	 N/N 	 1 	 tachycardia supraventricular
10 	 9 	 (S[dcl]\NP)/PP 	 2 	 to leads
11 	 10 	 PP/NP 	 1 	 dizziness to
13 	 10 	 PP/NP 	 1 	 fainting to
<\s>
<s id="wsj_0318.3"> 9
3 	 0 	 NP[nb]/N 	 1 	 heart The
3 	 1 	 N/N 	 1 	 heart typical
3 	 2 	 N/N 	 1 	 heart healthy
3 	 4 	 (S[dcl]\NP)/NP 	 1 	 heart beats
6 	 4 	 (S[dcl]\NP)/NP 	 2 	 times beats
6 	 5 	 N/N 	 1 	 times 70
6 	 7 	 (NP\NP)/N 	 1 	 times a
8 	 7 	 (NP\NP)/N 	 2 	 minute a
<\s>
<s id="wsj_0318.4"> 19
1 	 0 	 NP[nb]/N 	 1 	 drug The
1 	 3 	 (S[pss]\NP)/NP 	 1 	 drug called <XB>
1 	 6 	 ((S[dcl]\NP)/PP)/NP 	 1 	 drug returns
4 	 3 	 (S[pss]\NP)/NP 	 2 	 adenocard called
6 	 13 	 ((S\NP)\(S\NP))/NP 	 2 	 returns within
6 	 16 	 ((S\NP)\(S\NP))/PP 	 2 	 returns according
8 	 6 	 ((S[dcl]\NP)/PP)/NP 	 3 	 heart returns
8 	 7 	 NP[nb]/N 	 1 	 heart the
9 	 6 	 ((S[dcl]\NP)/PP)/NP 	 2 	 to returns
12 	 9 	 PP/NP 	 1 	 rhythm to
12 	 10 	 NP[nb]/N 	 1 	 rhythm a
12 	 11 	 N/N 	 1 	 rhythm normal
14 	 13 	 ((S\NP)\(S\NP))/NP 	 3 	 seconds within
17 	 16 	 ((S\NP)\(S\NP))/PP 	 3 	 to according
18 	 17 	 PP/NP 	 1 	 Lyphomed to
<\s>
<s id="wsj_0318.5"> 17
1 	 0 	 N/N 	 1 	 Research Medco
1 	 2 	 (S[dcl]\NP)/NP 	 1 	 Research developed
1 	 6 	 (((S[dcl]\NP)/PP)/PP)/NP 	 1 	 Research licensed <XU>
4 	 2 	 (S[dcl]\NP)/NP 	 2 	 drug developed
4 	 3 	 NP[nb]/N 	 1 	 drug the
7 	 6 	 (((S[dcl]\NP)/PP)/PP)/NP 	 4 	 it licensed
8 	 6 	 (((S[dcl]\NP)/PP)/PP)/NP 	 3 	 to licensed
9 	 8 	 PP/NP 	 1 	 Lyphomed to
10 	 6 	 (((S[dcl]\NP)/PP)/PP)/NP 	 2 	 for licensed
11 	 10 	 PP/NP 	 1 	 sale for
11 	 12 	 (NP\NP)/NP 	 1 	 sale in
14 	 12 	 (NP\NP)/NP 	 2 	 U.S. in
14 	 13 	 NP[nb]/N 	 1 	 U.S. the
16 	 12 	 (NP\NP)/NP 	 2 	 Canada in
<\s>
